Vermillion Reports Third Quarter 2007 Financial Results and Business Progress

“During the third quarter of 2007, we accomplished several important milestones including completion of enrollment of our ovarian cancer diagnostic clinical trial and securing $20.6 million from a private placement. In addition, we changed the Company’s name to Vermillion, Inc. to reflect our focus on specialty clinical diagnostic tests,” said Gail S. Page, President and Chief Executive Officer of Vermillion.
CNN Money